Feasible options include enrollment into clinical trials and use of targeted therapies such as gilteritinib for AML with FLT3 mutation [10, 13], combination of the BCL-2 inhibitor venetoclax (VEN) with HMA, or cytarabine-based salvage chemotherapy [14, 15]. Here, FLT3 is linked to acute myeloid leukemia.